ASX:OPT - Opthea Stock Price, News, & Analysis

A$0.62
-0.04 (-6.06 %)
(As of 06/16/2019 04:00 PM ET)
Today's Range
A$0.62
Now: A$0.62
A$0.64
50-Day Range
A$0.60
MA: A$0.68
A$0.72
52-Week Range
A$0.50
Now: A$0.62
A$0.80
Volume116,477 shs
Average VolumeN/A
Market Capitalization$154.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9826 0399

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$187,574.00
Cash FlowA$0.16 per share
Book ValueA$0.16 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$154.64 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OPT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.

Opthea (ASX:OPT) Frequently Asked Questions

What is Opthea's stock symbol?

Opthea trades on the ASX under the ticker symbol "OPT."

Has Opthea been receiving favorable news coverage?

Headlines about OPT stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Opthea earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Opthea.

Who are some of Opthea's key competitors?

Who are Opthea's key executives?

Opthea's management team includes the folowing people:
  • Dr. Megan Baldwin Ph.D., MAICD, MD, CEO & Exec. Director
  • Mr. Michael Tonroe, CFO & Company Sec.
  • Mr. Richard Chadwick Ph.D., Head of Intellectual Property
  • Dr. Michael Gerometta, Head of CMC Devel.
  • Dr. Ian Leitch, Director of Clinical Research

What is Opthea's stock price today?

One share of OPT stock can currently be purchased for approximately A$0.62.

How big of a company is Opthea?

Opthea has a market capitalization of $154.64 million and generates $187,574.00 in revenue each year. View Additional Information About Opthea.

What is Opthea's official website?

The official website for Opthea is http://www.opthea.com/.

How can I contact Opthea?

The company can be reached via phone at 61 3 9826 0399.


MarketBeat Community Rating for Opthea (ASX OPT)

Community Ranking:  3.0 out of 5 (star star half star)
Outperform Votes:  3 (Thanks for Voting!)
Underperform Votes:  2 (Thanks for Voting!)
Total Votes:  5
MarketBeat's community ratings are surveys of what our community members think about Opthea and other stocks. Vote "Outperform" if you believe OPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel